Nevertheless, normal B‐cell aplasia and the subsequent agammaglobulinaemia are the most frequent off‐tumor effects of CD19‐targeted immunotherapy, and they can be treated by repeated administration of intravenous gamma globulin without a life‐threatening infection.24 The gene discussed is CD19; the disease is neoplasm.